logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Bisphosphonate class drugs

    FiltersReset Filters
    10 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • alendronate sodium

      (Alendronate Sodium)
      Hikma Pharmaceuticals USA Inc.
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It helps increase bone mass and reduce fracture incidence, particularly in the hip and spine. Re-evaluations for continued therapy are recommended every few years.

    • fosamax

      (alendronate sodium)
      Organon LLC
      Usage: FOSAMAX® is indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in men and women. Treatment duration and reevaluation of therapy needs are recommended periodically.

    • fosamax plus d

      (ALENDRONATE SODIUM and CHOLECALCIFEROL)
      Organon LLC
      Usage: FOSAMAX PLUS D is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It enhances bone mass and lowers the risk of fractures, but is not for treating vitamin D deficiency. Optimal duration and need for continued therapy must be periodically reassessed.

    • ibandronate sodium

      (Ibandronate sodium)
      Dr. Reddy's Laboratories Limited
      Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. They increase bone mineral density and reduce vertebral fractures. Continued therapy needs periodic evaluation, especially after 3 to 5 years for low-risk patients.

    • ibandronate sodium

      (Ibandronate Sodium)
      AuroMedics Pharma LLC
      Usage: Ibandronate sodium injection is indicated for treating postmenopausal osteoporosis, enhancing bone mineral density and reducing vertebral fractures. Its safety and effectiveness are based on one year of clinical data, with the need for continued therapy to be re-evaluated periodically. Consider discontinuation for low-risk fracture patients after 3-5 years.

    • ibandronate sodium

      (IBANDRONATE SODIUM)
      Apotex Corp
      Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of postmenopausal osteoporosis, increasing bone mineral density and reducing vertebral fractures. Optimal duration of use is not established; reevaluation of therapy need is recommended after 3-5 years, especially for low-risk fracture patients.

    • ibandronate sodium

      (IBANDRONATE SODIUM)
      Macleods Pharmaceuticals Limited
      Usage: Ibandronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mineral density and reducing vertebral fracture incidence. Ongoing therapy should be periodically re-evaluated, especially in patients at low fracture risk, who may consider discontinuation after 3 to 5 years of use.

    • ibandronate sodium

      (ibandronate sodium)
      Apotex Corp.
      Usage: Ibandronate sodium injection is indicated for treating osteoporosis in postmenopausal women, enhancing bone mineral density and decreasing vertebral fracture incidence. Its safety and effectiveness are primarily based on one-year clinical data, with ongoing assessment of therapy necessity recommended for patients.

    • ibandronate sodium

      (Ibandronate Sodium)
      Aurobindo Pharma Limited
      Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women, enhancing bone mineral density and reducing vertebral fractures. Long-term safety and effectiveness are uncertain; patients require periodic evaluations to determine the necessity for continued therapy.